John Sourbeer
Stock Analyst at UBS
(0.53)
# 3,885
Out of 4,761 analysts
36
Total ratings
29.41%
Success rate
-29.41%
Average return
Main Sectors:
Stocks Rated by John Sourbeer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QDEL QuidelOrtho | Maintains: Neutral | $43 → $45 | $40.46 | +11.22% | 3 | Feb 13, 2025 | |
| QGEN Qiagen | Maintains: Neutral | $50 → $48 | $39.57 | +21.30% | 4 | Feb 7, 2025 | |
| WST West Pharmaceutical Services | Upgrades: Buy | $350 → $390 | $210.91 | +84.91% | 3 | Dec 12, 2024 | |
| PACB Pacific Biosciences of California | Downgrades: Neutral | $2 | $1.54 | +29.87% | 3 | Nov 11, 2024 | |
| ILMN Illumina | Maintains: Neutral | $133 → $145 | $94.20 | +53.93% | 3 | Nov 5, 2024 | |
| OMIC Singular Genomics Systems | Maintains: Neutral | $12 → $15 | $20.01 | -25.04% | 2 | Mar 20, 2024 | |
| CYRX Cryoport | Maintains: Neutral | $15 → $17 | $6.22 | +173.31% | 4 | Mar 15, 2024 | |
| MEDP Medpace Holdings | Maintains: Buy | $452 → $480 | $340.22 | +41.09% | 4 | Mar 8, 2024 | |
| AKYA Akoya Biosciences | Maintains: Buy | $7 → $7.5 | $2.05 | +265.85% | 2 | Mar 5, 2024 | |
| BRKR Bruker | Maintains: Buy | $94 → $102 | $50.82 | +100.71% | 3 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $50 | $10.90 | +358.72% | 1 | Feb 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $270 | $201.39 | +34.07% | 1 | Sep 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $142 → $128 | $134.92 | -5.13% | 2 | Jul 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $22 | $20.90 | +5.26% | 1 | Aug 10, 2021 |
QuidelOrtho
Feb 13, 2025
Maintains: Neutral
Price Target: $43 → $45
Current: $40.46
Upside: +11.22%
Qiagen
Feb 7, 2025
Maintains: Neutral
Price Target: $50 → $48
Current: $39.57
Upside: +21.30%
West Pharmaceutical Services
Dec 12, 2024
Upgrades: Buy
Price Target: $350 → $390
Current: $210.91
Upside: +84.91%
Pacific Biosciences of California
Nov 11, 2024
Downgrades: Neutral
Price Target: $2
Current: $1.54
Upside: +29.87%
Illumina
Nov 5, 2024
Maintains: Neutral
Price Target: $133 → $145
Current: $94.20
Upside: +53.93%
Singular Genomics Systems
Mar 20, 2024
Maintains: Neutral
Price Target: $12 → $15
Current: $20.01
Upside: -25.04%
Cryoport
Mar 15, 2024
Maintains: Neutral
Price Target: $15 → $17
Current: $6.22
Upside: +173.31%
Medpace Holdings
Mar 8, 2024
Maintains: Buy
Price Target: $452 → $480
Current: $340.22
Upside: +41.09%
Akoya Biosciences
Mar 5, 2024
Maintains: Buy
Price Target: $7 → $7.5
Current: $2.05
Upside: +265.85%
Bruker
Mar 1, 2024
Maintains: Buy
Price Target: $94 → $102
Current: $50.82
Upside: +100.71%
Feb 2, 2023
Initiates: Neutral
Price Target: $50
Current: $10.90
Upside: +358.72%
Sep 7, 2022
Initiates: Buy
Price Target: $270
Current: $201.39
Upside: +34.07%
Jul 27, 2022
Maintains: Buy
Price Target: $142 → $128
Current: $134.92
Upside: -5.13%
Aug 10, 2021
Initiates: Neutral
Price Target: $22
Current: $20.90
Upside: +5.26%